Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 9694 Download: 401 Web of Science: 19 Crossref: 25

Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications

Xindi Ke, Shangze Jiang, Qiaoxin Wei, Minghao Sun, Hang Sun, Mingchang Pang, Mei Liu, Lejia Sun, Huayu Yang, Yilei Mao

Clin Mol Hepatol. 2025;31(3):685-705. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.1039

View: 7850 Download: 271 Web of Science: 2 Crossref: 2

Editorial

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):301-303. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0716

View: 5574 Download: 93 Web of Science: 2 Crossref: 3

Original Article

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 4231 Download: 182 Web of Science: 6 Crossref: 6

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk

Clin Mol Hepatol. 2021;27(1):110-124. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0125

View: 14063 Download: 510 Web of Science: 101 Crossref: 100

Editorial

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 7800 Download: 124 Web of Science: 20 Crossref: 20

Review

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0129

View: 15266 Download: 464 Web of Science: 64 Crossref: 72

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Emerging medical therapies for severe alcoholic hepatitis

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 10491 Download: 239 Web of Science: 21 Crossref: 21

Review

Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation

Lu Jiang, Lan-Duoduo Du, Jing Zeng, Hui-kuan Chu, Zhong Peng, Jian-Gao Fan

Received July 2, 2025 Accepted August 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0718 [Accepted]

View: 3058 Download: 126

Original Article

Bacteroides eggerthii Ameliorates MASLD through Host–Microbe Signaling and Highlights 2-Hydroxyisocaproate as a Potential Effector

Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim

Received May 4, 2025 Accepted October 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0475 [Accepted]

View: 635 Download: 90

1 |

Viewed By 19808	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 15642	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 11094	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 11077	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 9218	MAFLD: How is it different from NAFLD?

Cited By 434	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 420	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 278	MAFLD: How is it different from NAFLD?
Cited By 206	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Cited By 148	Non-alcoholic fatty liver disease: Definition and subtypes

Search